24 October 2025
24 October 2025
US pricing pressures come amid aggressive deal-making moves by Roche to bolster its internal pipeline.
IMU Biosciences' precision medicine platform maps the immune system to improve diagnosis, treatment, and healthcare outcomes.
The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.
The investment includes ramping up final assembly and packaging for blockbuster-in-waiting Nemluvio.
According to GlobalData, Series D rounds of financing saw the highest growth compared to Series A, B, C and E financing, rising 60-fold from Q2 2025 to a total of $832m.
The programme’s initial partners include start-ups Crysttal, Abolis and Alysophil.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
